ARVO International Advocacy Toolkit: China

1. Which organization/s are significant sources of research funding? (e.g., national/local governments; private funding/foundations/charity groups; large non-governmental organizations (NGOs); industry/pharmaceutical companies)

   National government.

2. What does the normal science funding/policy decision-making process look like?

   Which groupcommittee/person within the funding/policy organization makes the decisions?

   Peer review and committee evaluation.

   What are the criteria the funding/policy organization(s) use to make their decisions?

   Innovation and feasibility.

3. Which patient advocacy groups, if any, are active in the area?

   There are no significant patient advocacy groups.

4. Are there existing national/regional organizations that work towards improving research funding/policy (advocating for increased research funding/better policies)?

   China Association for Science and Technology and its branches.

5. How do scientists currently contribute to the existing funding/policymaking/advocacy process, if at all?

   Advisory committees and at public seminars.

6. When are science funding/policy decisions made?

   Annually on a set schedule.

7. What kinds of opportunities exist for scientists to interact with funders and policymakers?

   Can scientists invite decision makers to their lab/institution to see their work firsthand?

   No.

   Do the funding/policy organizations hold open meetings or solicit comments from the public that researchers can participate in?
No.

Contributors – YAO Ke, MD (Eye Institute of Zhejiang University)